CClinicalTrials.gg
TerminatedNCT01871168Updated Mar 25, 2020

Continuous TAP Blocks - Pain & Plasma LA Levels

An interventional study of TAP block and Sham TAP block in Nerve Block and Pain, Postoperative, sponsored by University of Alberta. Terminated at 1 site in Canada. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-03-25.

Sponsored by University of Alberta · Not applicable, Interventional, and Supportive care

Why this study was terminated
PI no longer at institution
Phase
Not applicable
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to establish an alternative method of postoperative pain control to the current standard of practice, patient-controlled analgesia with intravenous opioids, for patients undergoing a major major abdominal surgery at the University of Alberta Hospital. The primary objective is to determine whether a continuous transversus abdominis plane (TAP) block, run until the third postoperative day, will reduce the amount of intravenous morphine required. Additionally, the investigators propose to measure the amount of local anesthetic (lidocaine) in the blood during this time frame to provide patient safety data for this procedure. This will be a prospective controlled randomized double-blind clinical trial. The patients, anesthesiologists and staff providing post operative care will be blinded to group assignment. Patients will be randomized by sealed envelopes.

Read the detailed description

INTRODUCTION The use of peripheral nerve blocks has become increasingly popular in the last two decades. With the use of anatomical landmark-based techniques, peripheral nerve stimulators, or ultrasound-guided techniques, novel types of nerve blocks have been made possible with both new indications as well as a lower risk of complications for the patient. The transversus abdominis plane (TAP) block is a newly developed block involving the nerves of the anterior abdominal wall. Recent published clinical trials involving patients undergoing both major abdominal as well as gynaecological surgery, have demonstrated promising results with this technique as part of a multimodal post-operative pain treatment. There was a recent review article summarizing the results of the available studies. This review article presents a brief summary of the methods used for the TAP block. Clinical studies of the effect of the TAP block on post-operative pain were systematically searched and reviewed. Suggestions for future assessment and use of the TAP block were discussed. McDonnell and O'Donnell recently found a series of TAP Blocks placed via the triangle of Petit to be effective in reducing postoperative pain in major abdominal surgery. Hebbard suggests placing TAP blocks from a subcostal oblique approach for surgery above the umbilicus. Our personal experiences with postoperative analgesia via TAP blocks in patients undergoing supraumbilical laparotomy coincide with Dr.

Hebbard's opinion. This is why for this study we propose placing TAP catheters in our patients via a subcostal oblique approach. Pain following abdominal surgery is largely derived from abdominal wall incision. The anatomy of the abdominal wall and nerve supply is well described. The anterior abdominal wall has a central and lateral component. The central abdominal wall consists of the rectus sheath, which includes the rectus abdominal muscle, and associated fascial sheaths. The lateral wall consists of the external oblique, the internal oblique and the transversus abdominis muscles and their fascial sheaths. Sensory supply to the anterior abdominal wall including skin, muscle and parietal peritoneum is derived from the anterior rami of the lower six thoracic nerves and the first lumbar nerves. The nerves pass through the lateral fascial plane between the internal oblique and transversus abdominis muscles termed the transversus abdominis fascial plane. These nerves can be blocked utilizing the transversus abdominis plane block using a double pop technique or using ultrasound. Preliminary volunteer and cadaveric studies have demonstrated the potential for the TAP block to produce a dermatomal sensory block of the lower six thoracic and first lumbar abdominal afferents.

Postoperative analgesia for patients undergoing major abdominal surgery, such as hepatectomy, liver transplantation, or Whipple's Surgery is an issue of debate in the anesthetic society. While epidural analgesia is widely accepted as the best method for postoperative pain control in most major abdominal surgery, the safety of epidural catheters in patients undergoing liver or pancreatic resections is contested. Postoperative coagulopathy, which develops to an extent in every patient with resection of liver and which is directly correlated to the amount of liver resected, puts the patient at risk of developing a spinal hematoma - particularly with removal of the catheter. Coagulopathy also exists to a degree in patients with pancreatic cancer and obstructive jaundice, therefore the question as to the safety of an epidural catheter in these patients is debatable. As large doses of anesthetic are injected into a relatively vascular area during TAP blocks, there exists the potential for toxicity. Two recent studies have examined serum levels of lidocaine and ropivacaine after TAP block using standard local anesthetic volumes and found serum levels consistent with potential systemic toxicity. However, there is no literature on serum local anesthetic levels during continuous TAP block. Serum lidocaine plasma levels will be measured in patients randomized to receive TAP block with or without intermittent local anesthetic bolusing postoperatively to provide patient safety data for this procedure. OBJECTIVE To determine whether a continuous transversus abdominis plane block run until the third postoperative day will reduce patient postoperative pain scores and reduce the amount of intravenous morphine required for major abdominal surgery and to quantify plasma lidocaine levels. HYPOTHESIS Patients receiving continuous TAP block with lidocaine use less PCA morphine post-operatively compared to patients receiving placebo through TAP catheters. METHODS Following Institutional Ethics Board Approval, forty patients undergoing major abdominal surgery (the number was chosen according to previous similar studies) will be randomly allocated to TAP block with postoperative intermittent infusion of 0.5-1.0% lidocaine versus TAP block with postoperative intermittent infusion of placebo (i.e. saline). All patients will receive a standard general anesthetic and all patients will receive the current postoperative analgesic standard of care in our hospital, which is an intravenous morphine PCA pump combined with adjunctive medication. The presence and severity of pain, sedation and nausea will be assessed by an investigator blinded to group allocation. These assessments will be done by one of the investigators at 24, 48, 72, and 96 hours after the TAP blockade. Pain will be assessed at rest and on movement using the visual analogue score. Sedation scores shall be assigned to awake or alert=0, quietly awake=1, asleep but easily aroused=2, deep sleep=3. Sedation will be defined as the presence of sedation score greater than 0 at any time point. Nausea will be defined by the administration of rescue antiemetics. Morphine requirements at 24, 48, 72, and 96 hours will be assessed for all patients. Also we will evaluate any extra medication a patient may have required, time to first bowel movement, time to first mobilization, discharge date, and any complications such as wound infection, ileus, local anesthetic toxicity, or catheter dislocation. All patients who have a unilateral incision will receive a TAP catheter placed intraoperatively by the surgeon. Under direct visualization, the surgeon will first close the muscle layer of the transversus abdominis.

Then a standard nerve block catheter will be inserted percutaneously from just lateral to the rectus abdominis muscle cephalad to the incision. The catheter will then be placed in an oblique direction along the border of the 12th rib and the tip will be placed as far lateral as the incision allows without dissecting any further tissue. The surgeon will then close the muscle layer of the internal oblique over the catheter and in a third layer close the external oblique and subcutaneous tissue before closing skin. The catheter will be fixed to skin via a specialized taping system, which we use to secure all nerve catheters, obliviating the need to suture the catheter to skin and thus running the risk of occluding it. In the event that surgical incision crosses midline and is bilateral, the surgeon will place a second TAP catheter in the method described above on the contralateral side. Our postoperative pain regimen will include the following. All patients will receive the current standard of care in our hospital, which is an intravenous morphine PCA pump. Additionally the patient will be able to receive a breakthrough dose of i.v. morphine prn. All patients will have adjunctive medications ordered.

Regarding infusion into the TAP catheter, all patients will receive intermittent boluses of either lidocaine (0.5-1.0%, at the discretion of the anesthesiologist) or placebo into their TAP catheters. For patients with unilateral incisions, a bolus of 20-40 ml will be applied every four to eight hours by our pumps. A KVO rate of 1 ml per hour will run throughout. Should it be necessary to place catheters bilaterally, we will set a second pump for the second catheter. This pump will be set with identical settings, i.e. will deliver 20-40 ml of solution every four to eight hours. Blood will be sampled for plasma lidocaine levels through the already sited intravenous line at 30 minutes postoperatively, as well as immediately before and 30 minutes after one local anesthetic or placebo bolus each day for three days postoperatively. The TAP catheter will be removed after approximately 72 hours on the morning of the third postoperative day.

02

Conditions studied

  • Nerve Block
  • Pain, Postoperative

Browse trials for

03

In context

Pain, Postoperative

5,093 studies on the registry are indexed under Pain, Postoperative; 1,140 are open to participants now.

This study's enrollment of 57 is below the median of 75 across 4,344 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

University of Alberta is the lead sponsor of 800 studies on the registry; 168 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adult patients undergoing major abdominal surgery who consent to a continuous transversus abdominis nerve block as part of their postoperative management

Exclusion criteria

Exclusion Criteria:

  • History of allergy to local anesthesia
  • Infection in the area of intended catheter insertion
  • Opiate tolerance
  • Failure to consent
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
57 participants (actual)

Study arms

  • Sham comparator
    Sham TAP block

    Patients receive TAP catheters but saline infusion instead of local anesthetic

    Procedure: Sham TAP block

  • Experimental
    TAP block

    Patients receive a continuous TAP block

    Procedure: TAP block

Interventions

  • ProcedureTAP block

    Infusion of 0.5-1% lidocaine

  • ProcedureSham TAP block

    Infusion of saline

06

What researchers measure

Primary outcomes

  1. Morphine requirements following major abdominal surgery

    Morphine consumption will be measured every 24 hours following surgery.

    Time frame: 96 hours post-surgery

Secondary outcomes

  1. Pain

    Pain will be recorded every 24 hours following surgery on a VAS scale.

    Time frame: 96 hours post-surgery

  2. Sedation

    Sedation will be assessed every 24 hours following surgery using a 4-point scale.

    Time frame: 96 hours post-surgery

  3. Nausea

    Nausea will be assessed every 24 hours following surgery using a 4-point scale.

    Time frame: 96 hours post-surgery

  4. Systemic effects of lidocaine

    Blood will be sampled for plasma lidocaine levels through the already sited intravenous line at 30 minutes postoperatively, as well as immediately before and 30 minutes after one local anesthetic or placebo bolus each day for three days postoperatively.

    Time frame: 72 hours post-surgery

07

Study locations

1 site
  • University of Alberta Hospital
    Edmonton, Alberta T6G 2G3, Canada
08

References and documents

Publications

  • Petersen PL, Mathiesen O, Torup H, Dahl JB. The transversus abdominis plane block: a valuable option for postoperative analgesia? A topical review. Acta Anaesthesiol Scand. 2010 May;54(5):529-35. doi: 10.1111/j.1399-6576.2010.02215.x. Epub 2010 Feb 17. PubMed 20175754 ↗
  • McDonnell JG, O'Donnell B, Curley G, Heffernan A, Power C, Laffey JG. The analgesic efficacy of transversus abdominis plane block after abdominal surgery: a prospective randomized controlled trial. Anesth Analg. 2007 Jan;104(1):193-7. doi: 10.1213/01.ane.0000250223.49963.0f. Erratum In: Anesth Analg. 2007 May;104(5):1108. PubMed 17179269 ↗
  • Hebbard P. Subcostal transversus abdominis plane block under ultrasound guidance. Anesth Analg. 2008 Feb;106(2):674-5; author reply 675. doi: 10.1213/ane.0b013e318161a88f. No abstract available. PubMed 18227342 ↗
  • Kato N, Fujiwara Y, Harato M, Kurokawa S, Shibata Y, Harada J, Komatsu T. Serum concentration of lidocaine after transversus abdominis plane block. J Anesth. 2009;23(2):298-300. doi: 10.1007/s00540-008-0721-4. Epub 2009 May 15. PubMed 19444577 ↗
  • Griffiths JD, Barron FA, Grant S, Bjorksten AR, Hebbard P, Royse CF. Plasma ropivacaine concentrations after ultrasound-guided transversus abdominis plane block. Br J Anaesth. 2010 Dec;105(6):853-6. doi: 10.1093/bja/aeq255. Epub 2010 Sep 22. PubMed 20861094 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01871168
Lead sponsor
University of Alberta
Responsible party
Sponsor
First posted
Jun 6, 2013
Start date
May 2013
Primary completion
Nov 2016
Completion
Nov 2017
Last update
Mar 25, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion